Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.39 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7541956 | 0.99 | ADORA1 (0.52) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7485481 | 0.89 | ADORA1 (0.52) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7488376 | 0.89 | ADORA1 (0.51) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7496245 | 0.89 | ADORA1 (0.48) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7668541 | 0.88 | ADORA1 (0.53) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7494888 | 0.88 | ADORA1 (0.50) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7487132 | 0.88 | ADORA1 (0.52) | ADORA1MAPK1IGF1RAKT1 | |
| SCHEMBL7488103 | 0.88 | ADORA1 (0.52) | ADORA1MAPK1IGF1RAKT1EGFR | |
| SCHEMBL7663464 | 0.87 | ADORA1 (0.53) | ADORA1MAPK1IGF1RAKT1MAPK14 | |
| SCHEMBL7490771 | 0.87 | ADORA1 (0.52) | ADORA1MAPK1IGF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | claimed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | claimed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| US-20260001881-A1 | COMPOUNDS AND METHODS FOR MODULATION OF G-PROTEIN-COUPLED RECEPTORS | PRIMETIME LIFE SCIENCES LLC (US) | 2026-01-01 | — | — | US | disclosed |
| CN-117321080-A | Combination therapy using anti-CD 38 antibodies and PARP or adenosine receptor inhibitors | 詹森生物科技公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4294844-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | Janssen Biotech, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | JANSSEN BIOTECH, INC. | 2022-09-01 | — | — | US | disclosed |
| WO-2022175920-A1 | COMBINATION THERAPIES WITH ANTI-CD38 ANTIBODIES AND PARP OR ADENOSINE RECEPTOR INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-114053269-A | Adenosine A1/A2ADual receptor antagonists | 南开大学 | 2022-02-18 | — | — | CN | disclosed |
| US-10696972-B2 | Method for improving learning | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2011123518-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-10-06 | — | — | WO | disclosed |
| EP-0925299-B1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6124456-A | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0925299-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998003507-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275090-A1 | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors | CD38, PARP1, PARP11 | ADORA1 25/4885MAPK1 3471/4885IGF1R 1932/4885 |
| US-20260001881-A1 | COMPOUNDS AND METHODS FOR MODULATION OF G-PROTEIN-COUPLED RECEPTORS | GRK2, ARRB1, GPR3 | ADORA1 215/4885MAPK1 1007/4885IGF1R 403/4885 |
| US-20180030453-A1 | METHOD FOR IMPROVING LEARNING | NT5E, ADORA1, ENTPD5 | ADORA1 2/4885MAPK1 3104/4885IGF1R 763/4885 |
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | ADORA1 9/4885MAPK1 4287/4885IGF1R 1542/4885 |
| US-10696972-B2 | Method for improving learning | NT5E, ADORA1, ENTPD5 | ADORA1 2/4885MAPK1 3104/4885IGF1R 763/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ADORA1 348/4885MAPK1 3664/4885IGF1R 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.